GCC19CART for Patients With Metastatic Colorectal Cancer Post author: Post published:March 1, 2026 Post category: Continue ReadingGCC19CART for Patients With Metastatic Colorectal Cancer
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM Post author: Post published:March 1, 2026 Post category: Continue ReadingIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors Post author: Post published:March 1, 2026 Post category: Continue ReadingPhase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Post author: Post published:March 1, 2026 Post category: Continue ReadingHumanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL Post author: Post published:March 1, 2026 Post category: Continue ReadingBAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Post author: Post published:March 1, 2026 Post category: Continue ReadingModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
